ErbB2 (ErbB2/HER2/Neu) is a member of the ErbB family of receptor tyrosine kinases, a family that also includes the Epidermal Growth Factor (EGF) Receptor (EGFR/ErbB1), ErbB3 (HERS), and ErbB4/HER4. Increased expression and signaling by ErbB2/HER2/Neu is observed in a significant fraction of mammary, ovarian, and prostate cancer patients, where they are correlated with tumor metastasis and poor prognosis. Consequently, our goal is to develop a positron emission tomography (PET) imaging agent that can be used to detect tumor cells that overexpress ErbB2. Such an agent could be used to noninvasively detect primary and metastatic tumor cells that overexpress ErbB2. Such an agent is not currently available. Our strategy is to express the extracellular domain of ErbB2 as a recombinant, soluble, epitope-tagged protein (s-ecErbB2). We will then couple s-ecErbB2 to a support matrix to create an affinity reagent that can be used to screen for molecules that bind s-ecErbB2. We will use this affinity reagent to screen a library of random, single-stranded oligodeoxynucleotides for those oligos (aptamers) that bind to s- ecErbB2. These aptamers will be radiolabeled and assayed for specific binding to ErbB2 overexpressed in a cultured cell line. Ultimately, these experiments should lead to the generation of 18F-labeled, nuclease-resistant aptamers that may be useful PET imaging agents. However, the generation and testing of 18F-labeled aptamers is beyond the scope of this proposal. Thus, the two specific aims of this proposal are to (1) express s- ecErbB2 and immobilize it on a chromatography support matrix; and (2) use this affinity reagent to screen a library of random DNA oligonucleotides for those aptamers that specifically bind s-ecErbB2 and assay the selected aptamers for binding to ErbB2 that is overexpressed on the surface of cultured cell lines.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21CA089274-02
Application #
6522758
Study Section
Diagnostic Radiology Study Section (RNM)
Program Officer
Menkens, Anne E
Project Start
2001-08-23
Project End
2004-07-31
Budget Start
2002-08-01
Budget End
2004-07-31
Support Year
2
Fiscal Year
2002
Total Cost
$150,000
Indirect Cost
Name
Purdue University
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
072051394
City
West Lafayette
State
IN
Country
United States
Zip Code
47907
Wilson, Kristy J; Mill, Christopher P; Cameron, Elizabeth M et al. (2007) Inter-conversion of neuregulin2 full and partial agonists for ErbB4. Biochem Biophys Res Commun 364:351-7
Gilmore, Jennifer L; Gallo, Richard M; Riese 2nd, David J (2006) The epidermal growth factor receptor (EGFR)-S442F mutant displays increased affinity for neuregulin-2beta and agonist-independent coupling with downstream signalling events. Biochem J 396:79-88
Gallo, Richard M; Bryant, Ianthe; Fry, Rachael et al. (2006) Phosphorylation of ErbB4 on Tyr1056 is critical for inhibition of colony formation by prostate tumor cell lines. Biochem Biophys Res Commun 349:372-82
Hobbs, Stuart S; Gallo, Richard M; Riese Jr, David J (2005) Phe45 of NRG2beta is critical for the affinity of NRG2beta for ErbB4 and for potent stimulation of ErbB4 signaling by NRG2beta*. Growth Factors 23:273-83
Hobbs, Stuart S; Cameron, Elizabeth M; Hammer, Robert P et al. (2004) Five carboxyl-terminal residues of neuregulin2 are critical for stimulation of signaling by the ErbB4 receptor tyrosine kinase. Oncogene 23:883-93
Gilmore, Jennifer L; Riese 2nd, David J (2004) secErbB4-26/549 antagonizes ligand-induced ErbB4 tyrosine phosphorylation. Oncol Res 14:589-602